Access Biotechnology

Access Biotechnology is the dedicated healthcare investment arm of Access Industries, a privately held industrial group with diverse global interests. Based in New York, the firm specializes in partnering with private and public biopharmaceutical companies that are developing innovative and potentially transformative medicines. Their investment strategy is broad, encompassing all stages of development, from early-stage research and development through to commercialization. This flexibility allows them to support companies across their entire growth trajectory, reflecting a long-term commitment to the biopharma sector.

The firm has demonstrated significant growth and commitment to the life sciences sector through the successful raising of multiple dedicated funds. Their initial fund, Fund I, closed in 2018 with $300 million in capital. This was followed by Fund II in 2021, which secured $400 million, further expanding their capacity to invest. Most recently, Access Biotechnology closed Fund III, also with $400 million, bringing their total capital under management to approximately $1.1 billion across these three dedicated biotechnology funds. This substantial capital base underscores their ability to make meaningful investments and provide sustained support to their portfolio companies.

Access Biotechnology typically deploys significant capital in its initial investments, with a reported check size ranging from $10 million to $75 million. This range indicates their capacity to lead or co-lead substantial rounds, particularly in later-stage private companies or public entities, while also supporting promising early-stage ventures. The firm prides itself on a team that combines deep scientific, medical, and operational expertise with extensive investment experience. This integrated approach allows them to provide strategic guidance beyond just capital, aiming to foster the development of groundbreaking therapies that address unmet medical needs. Their focus remains on identifying and nurturing companies poised to make a significant impact on global health.